Buy the Breakout: Merck Momentum After Cancer Vaccine Readout Looks Sustainable
Merck rallied more than 14% today following reports of a positive cancer vaccine readout in collaboration with Moderna. The move leaves the stock extended but supported by strong free cash flow ($16.06B), a $369B market cap and an attractive dividend yield (~2.49%). We outline a mid-term trade plan to buy a breakout, set a protective stop, and targ…